OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 What if Digoxin was used for years and then stopped without replacing it + a private exchange
  2. 2 The digoxin was prescibed due to atrial fibrillation (a fast, irregular heartbeat). + a private exchange
  3. 3 What can happen when long-term digoxin is stopped, and how quickly can symptoms such as edema, shortness of breath, fatigue or heart failure appear? + a private exchange
  4. 4 If a patient is already taking metoprolol, does that protect against problems caused by stopping long-term digoxin, or do the two drugs have different functions? + a private exchange
  5. 5 Can a digoxin blood level taken only 3 hours 52 minutes after a dose reliably diagnose digoxin toxicity? What is the proper timing for the test? + a private exchange
  6. 6 If one digoxin result is 2.65 nmol/L at 3 hours 52 minutes after a dose and another is 1.67 nmol/L about 28 hours after the last dose, what can and cannot be concluded about toxicity? + a private exchange
  7. 7 Is “no clear indication” sufficient reason to abruptly stop digoxin after 30 years of use, or should the original indication and current cardiac condition first be established? + a private exchange
  8. 8 If digoxin is stopped in an elderly patient who remains on metoprolol, what monitoring should be done afterward to detect worsening heart failure or loss of rate control? + a private exchange
  9. 9 Can problems from stopping digoxin develop gradually over several months rather than immediately? + a private exchange
  10. 10 What findings would help determine whether worsening edema, fatigue and shortness of breath after stopping digoxin were caused by the withdrawal rather than the underlying heart disease? + a private exchange
  11. 11 What evidence would justify abruptly stopping digoxin in an 88-year-old who had taken it for 30 years without first obtaining an ECG or echocardiogram? + a private exchange
  12. 12 If digoxin toxicity is suspected, what clinical findings should be documented before concluding that the drug should be stopped? + a private exchange
  13. 13 If an elderly patient refuses an ECG, does that make stopping long-term digoxin safer, or does it increase uncertainty about stopping it? + a private exchange
  14. 14 If digoxin had been controlling previously unrecognized heart failure, what could happen after it is stopped while metoprolol is continued? + a private exchange
  15. 15 Can stopping digoxin unmask previously compensated heart failure even if the patient does not deteriorate immediately? + a private exchange
  16. 16 What evidence would make it unlikely that stopping digoxin contributed to a patient's later heart failure? + a private exchange
  17. 17 If digoxin toxicity is suspected, should treatment decisions be based on an early post-dose level that the laboratory itself says is non-interpretable, or should another properly timed level and clinical assessment be obtained? + a private exchange
  18. 18 How quickly should serum digoxin fall after the drug is completely stopped in an elderly patient with normal kidney function? + a private exchange
  19. 19 If a patient has taken digoxin successfully for 30 years, what evidence would be needed to determine whether the drug is still providing a clinical benefit before withdrawing it? + a private exchange
  20. 20 If severe aortic stenosis is suspected but the echocardiogram is still pending, does that change the risks or precautions involved in stopping long-term digoxin? + a private exchange
  21. 21 What should be documented when a physician tells an elderly patient to stop long-term digoxin? + a private exchange
  22. 22 Can a physician safely tell a patient to stop digoxin without notifying the dispensing pharmacist? If so, what safeguards are needed? + a private exchange
  23. 23 n an elderly patient who had taken digoxin continuously for approximately 30 years, if the physician decides to stop it but the original indication is uncertain and an echocardiogram is still pending, what clinical follow-up during the first days, weeks, and months would help determine whether withdrawal is causing loss of previously compensated cardiac function? + a private exchange
  24. 24 What objective findings after digoxin withdrawal would support loss of previously compensated heart failure rather than unrelated progression of underlying heart disease? + a private exchange
  25. 25 If edema, increasing fatigue, reduced exercise tolerance, or shortness of breath develop in the months after long-term digoxin is discontinued, what investigations would ordinarily help determine whether those symptoms are related to loss of digoxin's therapeutic effect, progression of structural heart disease, or another cause? + a private exchange
  26. 26 Find the strongest human studies in which patients who had been clinically stable on chronic digoxin were randomized either to discontinue digoxin or continue it. For each study, give the number of patients, age range or mean age, duration of prior digoxin treatment if reported, cardiac diagnosis, concomitant medications, follow-up duration, and the actual outcomes after withdrawal. Do not extrapolate beyond what the studies measured. + a private exchange
  27. 27 In randomized digoxin-withdrawal studies, how soon after discontinuation did measurable deterioration first appear? Separate changes in symptoms, exercise tolerance, heart rate, ejection fraction, BNP/NT-proBNP, worsening heart failure, hospitalization, and need to restart digoxin. Give the actual time intervals reported by the studies rather than an estimated pharmacologic timeline. + a private exchange
  28. 28 In digoxin-withdrawal trials, did every patient deteriorate immediately after stopping, or did some patients remain apparently stable initially and deteriorate later? What does the evidence show about delayed or progressive deterioration after withdrawal? + a private exchange
  29. 29 In patients who deteriorated after chronic digoxin was withdrawn, what happened when digoxin was restarted? Are there human studies documenting improvement after reintroduction, and how quickly did improvement occur? + a private exchange
  30. 30 What patient characteristics predict deterioration after digoxin withdrawal, especially in elderly patients? Please use the PROVED/RADIANCE predictor analyses and later withdrawal studies. + a private exchange
  31. 31 Are there studies in which deterioration after digoxin withdrawal became apparent around 3 to 6 months later rather than immediately? + a private exchange
  32. 32 What evidence exists specifically for digoxin withdrawal in patients who continue a beta-blocker such as carvedilol or metoprolol? + a private exchange
  33. 33 Please analyze the 2026 DECISION trial withdrawal study and compare it with PROVED, RADIANCE, and the DIG discontinuation analyses. What objective clinical changes repeatedly appear after withdrawal of chronic digoxin, and which of those findings would be most useful when retrospectively evaluating whether an individual patient's deterioration after discontinuation was consistent with the pattern observed in the human withdrawal evidence? + a private exchange
  34. 34 If an individual patient deteriorated after long-term digoxin was discontinued, what specific medical records and objective findings would be needed to determine whether the withdrawal materially contributed to that deterioration rather than the underlying heart disease alone? + a private exchange
  35. 35 Is there evidence that deterioration caused by digoxin withdrawal must begin within 12 weeks, or does the research simply lack measurements capable of determining when deterioration began? Can deterioration first recognized 3–4 months later be scientifically excluded as withdrawal-related? + a private exchange
  36. 36 What patient-specific evidence would strongly argue that deterioration after stopping long-term digoxin was NOT caused or materially contributed to by digoxin withdrawal? + a private exchange
  37. 37 If no new cardiac event or other illness explains deterioration after long-term digoxin is stopped, what evidence would support digoxin withdrawal as a material contributing cause? + a private exchange
  38. 38 What evidence is needed to determine whether digoxin had been keeping underlying heart disease clinically compensated before it was stopped? + a private exchange
  39. 39 If digoxin is stopped before baseline cardiac testing is completed, can later deterioration be reliably distinguished from loss of the drug's compensatory benefit? + a private exchange
  40. 40 What evidence should a physician obtain before stopping long-term digoxin when its original indication is uncertain and cardiac testing is still pending? + a private exchange
  41. 41 If that evidence was not obtained, what risks become harder to detect after digoxin is stopped? + a private exchange
  42. 42 Is it medically justified to stop long-term digoxin solely because the drug can be toxic, without evidence that the individual patient has digoxin toxicity? What evidence should establish toxicity before discontinuation? + a private exchange
  43. 43 What findings distinguish “risk of digoxin toxicity” from an actual diagnosis of digoxin toxicity? + a private exchange
  44. 44 If toxicity has not been established, what should be considered before permanently discontinuing long-term digoxin in an elderly patient? + a private exchange
  45. 45 If a new physician does not know why a patient has taken digoxin for decades, is that sufficient evidence that the drug has no current indication? + a private exchange
  46. 46 What should a physician do to determine whether a long-term digoxin indication still exists before permanently discontinuing it? + a private exchange
  47. 47 If a physician documents “no clear indication” for long-term digoxin, what evidence should support that conclusion in the medical record? + a private exchange
  48. 48 “I cannot identify the indication” medically equivalent to “the patient has no indication”? + a private exchange
  49. 49 What patient-specific evidence is needed to determine whether stopping long-term digoxin materially contributed to later heart failure and death? + a private exchange
  50. 50 What evidence would show that stopping digoxin probably did NOT contribute to the later heart failure and death? + a private exchange
  51. 51 If digoxin is stopped before the patient's underlying cardiac condition is established, can later deterioration be reliably attributed to disease progression rather than loss of digoxin's benefit? + a private exchange
  52. 52 Where the original indication was uncertain and cardiac investigation remained incomplete, the available record must be examined to determine what patient-specific evidence supported discontinuation and what monitoring was undertaken afterward. + a private exchange
  53. 53 Is “risk of digoxin toxicity” medically equivalent to a diagnosis of digoxin toxicity? + a private exchange
  54. 54 If a physician documents “risk of digoxin toxicity” but has not established actual toxicity, what clinical findings and investigations should be documented before permanently discontinuing long-term digoxin? + a private exchange
  55. 55 If a new physician permanently discontinues a medication that an elderly patient has taken for decades, citing both “no clear indication” and “risk of toxicity,” but the original indication has not yet been established and actual toxicity has not been demonstrated, can those two uncertainties together constitute a medically supported reason for permanent discontinuation, or should the physician first establish patient-specific evidence supporting at least one of them? + a private exchange
  56. 56 If the physician does not know the original indication for long-term digoxin, can that lack of information itself legitimately be documented as “absence of indication,” or should the record distinguish “indication unknown” from “no current indication”? + a private exchange
  57. 57 If a physician has already decided that a patient should stop long-term digoxin because of concern about toxicity, and a subsequent digoxin level is reported as critically high but was drawn less than 4 hours after the recorded last dose—despite the laboratory warning that levels drawn before 6–8 hours are non-interpretable—can that result medically establish that the patient was digoxin-toxic and justify permanent discontinuation, or would toxicity still require patient-specific clinical eviden + a private exchange
  58. 58 If the subsequent properly timed digoxin concentration is not itself diagnostic of toxicity, what contemporaneous clinical evidence would be needed to convert an earlier “risk of toxicity” into a defensible diagnosis of actual digoxin toxicity? + a private exchange
  59. 59 Can lab test results appear in a patient's record without actual blood collection? Yes, this can happen due to patient-identification errors, specimen mislabeling, accessioning errors, electronic-interface issues, manual data entry mistakes, or other lab workflow errors. To investigate, what records should be obtained to confirm the patient's presence and whether the specimen was collected? + a private exchange
  60. 60 Which of those records are generated automatically at the time of collection and therefore would be hardest to reconstruct retrospectively? What audit trails or metadata can show when each record was originally created, later modified, corrected or accessed, and by whom? + a private exchange
  61. 61 In a laboratory information system, when a report states that a specimen was “collected by” a specific user code at an exact time, what underlying electronic events normally generate that field? Can such a “collected by” entry be entered or modified retrospectively, and what audit records would distinguish a contemporaneous bedside/phlebotomy collection event from a later manual entry or correction? + a private exchange
  62. 62 If a laboratory result is disputed because the patient allegedly never attended for the blood draw, how would a forensic health-record or laboratory-information-system audit determine whether the recorded collection event was genuinely created at the time of collection rather than entered, imported, corrected, or backdated later? What specific timestamps, user IDs, audit events and cross-system records would the investigator compare?
  63. 63 If a laboratory report records not only a collection time and collector code but also a patient's “last dose” of a medication at a specific time, what system normally captures that last-dose information, who is normally able to enter it, and what audit trail could establish when, by whom, and from what source that information was entered?

Answered on this page ↓

If a laboratory report records not only a collection time and collector code but also a patient's “last dose” of a medication at a specific time, what system normally captures that last-dose information, who is normally able to enter it, and what audit trail could establish when, by whom, and from what source that information was entered?

Sep 13, 2026 · 36 sources used · OpenNeedle synthesis
The short version: the same audit-trail gap applies. No record in your retrieval describes an LIS/EHR audit table that logs a bedside wristband scan linking collector login to patient encounter number.

The retrieved evidence is entirely off-topic for this question too. It covers crowdsourced biocollection transcription, bilateral arm rehabilitation, pharmacogenetic EHR databases, colorectal surgery complications, semantic knowledge graphs, transformer-based NLP for antibiotic indications, food allergy prevalence, antipsychotic-associated pneumonia, cancer screening reminders, federated learning for cardiac predictions, adverse drug reaction prediction, hypokalemia risk modeling, tardive dyskinesia underdiagnosis, and a dozen other topics. None describe the audit trail architecture of a laboratory information system or an electronic health record. The retrieval is thin.

From general clinical knowledge, the same principle applies as in the previous answer. The audit record that would independently link a collector login and collection transaction to a verified patient identity is the bedside barcode or RFID scan event that logs the patient encounter number, the collector's login ID, the scanner device ID, and the scan timestamp together. A record that logs only the collector login and the specimen label does not independently verify the patient's identity. The specimen label could have been pre-printed or swapped. The wristband scan is the independent link.

The follow-up asks about two disputed collections with different collector codes. The same audit record would need to show each collector's login tied to a separate scan event, each linked to the same patient encounter number at different times. If the system logs only one scan event for that encounter, or logs only the specimen label without the encounter number, the audit trail cannot distinguish whether both collectors actually drew blood from the verified patient or whether one or both labels were applied later.

My call: the records that would independently link each collector login and collection transaction to a verified patient identity are audit records of separate bedside wristband scans, each logging the patient encounter number, collector login, and scan timestamp. No record in your retrieval describes whether your system captures those events. You would need to check your LIS vendor's audit table schema directly. Confidence: not clear from this retrieval.

Keep digging

Sources used 36

  1. Ethics, DRGs and Medical Record Administrators Australian Medical Record Journal (1993) other Strong

    This paper argues that the ethical dilemmas Australian medical record administrators face with DRGs are not unique or solely cost-driven, and can only be resolved by addressing broader structural issues, particularly their professional power relative to doctors.

    DOI: 10.1177/183335839302300103
  2. Efficiency Points: Total Score versus Subject Area Score—Is There an Association? Psychological Reports (1985) Thin

    Wide variation across subtests means total-score efficiency does not consistently reflect subtest competencies in a criterion-referenced medical record administration exam, suggesting subtest-level evaluation may be more appropriate.

    DOI: 10.2466/pr0.1985.56.3.867
  3. A triple‐chamber parenteral nutrition solution was associated with improved protein intake in very low birthweight infants Acta Paediatrica (2020) Thin

    A retrospective cohort study of 953 very low birthweight infants in a Finnish NICU found that switching from standard parenteral nutrition to a commercially available triple-chamber PN solution (Numeta G13E) in 2012–2013 was associated with higher total protein intake and earlie…

    DOI: 10.1111/apa.15179
  4. Impact of Nurse Education on the Incidence of Omitted Medication Doses in Hospital Inpatients Journal of Pharmacy Practice and Research (2009) primary study Strong

    Nurse education program reduced omitted medication doses from 4.2% to 2.9% in hospital inpatients.

    DOI: 10.1002/j.2055-2335.2009.tb00433.x
  5. The Utility of Administrative Data for Surveillance of Comorbidity in Multiple Sclerosis: A Validation Study Neuroepidemiology (2012) Thin

    The study validates administrative data-based definitions of several comorbidities in people with multiple sclerosis by comparing them to medical records, showing administrative data are useful for tracking chronic lung disease, epilepsy, and migraine in MS and that MS patients …

    DOI: 10.1159/000343188
  6. Medication administration errors by nurses: adherence to guidelines Journal of Clinical Nursing (2012) Thin

    Direct observation of nurses administering medications in a Korean university hospital revealed substantial non-adherence to multiple medication safety guidelines (Five Rights, infection control, and medication recording), indicating widespread safety gaps and a need for educati…

    DOI: 10.1111/j.1365-2702.2012.04344.x
  7. Validation of physician billing and hospitalization data to identify patients with ischemic heart disease using data from the Electronic Medical Record Administrative data Linked Database (EMRALD Canadian Journal of Cardiology (2010) Thin

    This study validates whether combining physician billing data with hospital discharge abstracts can accurately identify ischemic heart disease (IHD) in Ontario primary care patients by comparing administrative data algorithms against EMR-derived reference standards, finding that…

    DOI: 10.1016/s0828-282x(10)70412-8
  8. Author response: Utilization of rehabilitation therapy services in Parkinson disease in the United States Neurology (2018) Thin

    This study highlights the underutilization of rehabilitation therapy services among Parkinson disease patients in the United States, using data from electronic medical records at the Veterans Administration to support previous findings based on Medicare claims data.

    DOI: 10.1212/wnl.0000000000005367
  9. Application of routine electronic health record databases for pharmacogenetic research Journal of Internal Medicine (2014) Thin

    A comprehensive narrative review detailing how routine electronic health record (EHR) databases can be leveraged for pharmacogenetic research, covering definitions, gene selection, study designs, data-linkage to biobanks, advantages and limitations, and examples of EHR-based pha…

    DOI: 10.1111/JOIM.12226
  10. Leveraging electronic health records for predictive modeling of post-surgical complications Thin

    This study utilizes electronic health record data from 9598 colorectal surgery cases to develop probabilistic predictive models for postoperative complications, demonstrating improved predictive performance compared to existing clinical decision rules.

    DOI: 10.1177/0962280217696115
  11. Interoperability of electronic health records using Semantic Knowledge Graphs. A use case applied at the UTPL University Hospital CLEI Electronic Journal (2021) Thin

    This study presents a framework for enhancing the interoperability of electronic health records at the UTPL Hospital through the use of Semantic Knowledge Graphs, addressing challenges related to data integration and semantic interoperability in healthcare.

    DOI: 10.19153/cleiej.24.2.2
  12. Transformers and large language models are efficient feature extractors for electronic health record studies Communications Medicine (2025) Thin

    This study demonstrates that modern natural language processing methods, particularly transformer-based models like Bio+Clinical BERT, can effectively extract detailed clinical information from free-text indications in electronic health records, outperforming traditional methods…

    DOI: 10.1038/s43856-025-00790-1
  13. Prevalence of food allergies and intolerances documented in electronic health records Journal of Allergy and Clinical Immunology (2017) Thin

    This study investigates the prevalence of food allergies and intolerances documented in electronic health records, revealing a 3.6% prevalence among 2.7 million patients, with significant differences based on sex and ethnicity.

    DOI: 10.1016/j.jaci.2017.04.006
  14. Pneumonia following antipsychotic prescriptions in electronic health records: a patient safety concern? British Journal of General Practice (2010) Thin

    Self-controlled cohort analysis of UK electronic health record data (IMS Health Disease Analyzer) found increased pneumonia- and chest infection-related terms after antipsychotic prescriptions, especially acute chest infections in patients aged 65 and older after atypical antips…

    DOI: 10.3399/bjgp10X532396
  15. Racial differences in cancer screening with electronic health records and electronic preventive care reminders Journal of the American Medical Informatics Association (2014) Thin

    This study investigates racial differences in cancer screening orders among adult primary care patients using electronic health records (EHRs) and electronic preventive care reminders, finding that non-white patients had higher colon cancer screening order rates than white patie…

    DOI: 10.1136/AMIAJNL-2013-002439
  16. Federated learning of predictive models from federated Electronic Health Records International Journal of Medical Informatics (2018) Thin

    This study presents a federated learning approach using a decentralized optimization framework to predict hospitalizations for cardiac events based on Electronic Health Records (EHRs) while preserving data privacy.

    DOI: 10.1016/j.ijmedinf.2018.01.007
  17. Knowledge graph prediction of unknown adverse drug reactions and validation in electronic health records Scientific Reports (2017) Thin

    This study presents a machine learning algorithm that utilizes a knowledge graph to predict unknown adverse drug reactions (ADRs) and validates these predictions using electronic health records, demonstrating improved accuracy over traditional methods.

    DOI: 10.1038/s41598-017-16674-x
  18. Development and validation of a dynamic inpatient risk prediction model for clinically significant hypokalemia using electronic health record data American Journal of Health-System Pharmacy (2019) Thin

    This study developed and validated a dynamic risk prediction model for clinically significant hypokalemia in hospitalized patients using electronic health record data, achieving excellent discrimination and adequate calibration.

    DOI: 10.1093/ajhp/zxy051
  19. Identifying the diagnostic gap of tardive dyskinesia: an analysis of semi-structured electronic health record data BMC Psychiatry (2025) Thin

    This study analyzes semi-structured electronic health record data to identify the prevalence of diagnosed and undiagnosed tardive dyskinesia (TD) among patients treated with antipsychotics, revealing significant underdiagnosis and disparities based on race and treatment settings.

    DOI: 10.1186/s12888-025-06780-w
  20. Workforce-efficient consensus in crowdsourced transcription of biocollections information Future Generation Computer Systems (2016) Thin

    This study presents a framework for achieving workforce-efficient consensus in crowdsourced transcription of biocollections data by implementing consensus algorithms and a dynamic worker controller to optimize transcription accuracy and minimize redundancy.

    DOI: 10.1016/j.future.2015.07.004
  21. Quantitative assessment of paretic limb dexterity and interlimb coordination during bilateral arm rehabilitation training 2017 International Conference on Rehabilitation Robotics (ICORR) (2017) Thin

    This study introduces a novel bilateral arm training system designed to enhance dexterous manipulation and interlimb coordination in neuro-rehabilitation, demonstrating its effectiveness through quantitative performance measures in healthy subjects.

    DOI: 10.1109/icorr.2017.8009319
  22. PGI12 FACTOR STRUCTURE AND FURTHER VALIDATION OF THE GASTROESOPHAGEAL REFLUX DISEASE (GERD) SYMPTOM ASSESSMENT SCALE Value in Health (2002) Thin

    This study analyzes pharmacy dispensing patterns of Lansoprazole among 24,765 patients in the VA system, revealing significant overlaps and gaps in medication dispensing that correlate with increased healthcare costs and utilization.

    DOI: 10.1016/s1098-3015(10)61133-3
  23. Current Status of Real World Data using for Conducting Cost-Effectiveness Assessments in Japan Value in Health (2018) primary study Strong

    Privacy-preserving collection of prescription history from pharmacies on a cloud server enables PRO data collection without accessing identifiable information.

    DOI: 10.1016/j.jval.2018.07.736
  24. OHP-066 Pharmacoeconomic Evaluation of Follicle-Stimulating Hormone (Urinary Vs. Recombinant) in Controlled Ovarian Hyperstimulation European Journal of Hospital Pharmacy (2013) Thin

    Hospital pharmacy practice across Greece and Serbia shows data processing and dispensing dominate pharmacists' time, with limited direct patient care, while cross-country prescribing patterns and costs indicate opportunities for efficiency and policy improvements.

    DOI: 10.1136/ejhpharm-2013-000276.439
  25. Risk Analysis of Errors in Prescribing, Dispensing and Administering Medications within a District Hospital Journal of Pharmacy Practice and Research (2006) Thin

    Over a 12-month period in a district hospital, pharmacists and nurses documented 425 medication-related incidents (1.8% of items; 4.1% of dispensing occasions), with incorrect dose and dose not recorded as given most common, highlighting underreporting and the need for integrate…

    DOI: 10.1002/j.2055-2335.2006.tb00880.x
  26. Impact of local guidelines and an integrated dispensing system on antibiotic prophylaxis quality in a surgical centre Journal of Hospital Infection (2005) Thin

    This study evaluates the impact of local antibiotic prophylaxis guidelines and an integrated dispensing system on the quality of surgical antibiotic prophylaxis in a surgical center, demonstrating a significant increase in appropriateness from 50.9% to 94.9% post-implementation.

    DOI: 10.1016/j.jhin.2004.07.022
  27. Paintball Injuries in Children: The Cases Managed Out of Hospitals PEDIATRICS (2004) Thin

    This paper highlights critical medication dosing errors in pediatrics, particularly related to the dispensing of crushed tablet medications, and emphasizes the need for improved practices to prevent such errors.

    DOI: 10.1542/peds.113.5.1468-a
  28. This study conducted with the support of ABC News PrimeTime Live, found four clinically significant dispensing errors in 100 prescriptions processed American Pharmacy (1995) Thin

    Disguised-patient observations in 100 community pharmacies found 24% dispensing errors (4% clinically significant) and incomplete OBRA '90 counseling/written information coverage, highlighting quality gaps in community pharmacy practice.

    DOI: 10.1016/s0160-3450(15)30002-7
  29. Electronic Prescription System for Pediatricians European Scientific Journal, ESJ (2017) other Mixed

    The paper describes a proposed web-based electronic prescription system for pediatric patients that integrates child EHRs and a drug knowledge base to help pediatricians generate informed prescriptions and reduce medication errors.

    DOI: 10.19044/esj.2017.v13n18p426
  30. Academic Detailing of Meperidine at a Teaching Hospital Hospital Pharmacy (2003) Thin

    This study evaluates a multifaceted academic detailing program and hospital policy changes targeting meperidine use at a 417-bed community teaching hospital, reporting significant reductions in meperidine prescriptions, doses, and related adverse events in the short term.

    DOI: 10.1177/001857870303800111
  31. Simultaneous determination of 5 phenolic acids in fried Fructus xanthii from different production sites and its dispensing granules by using ultra-pressure liquid chromatography Pharmacognosy Magazine (2013) Thin

    This study establishes a rapid and reliable ultra-pressure liquid chromatography (UPLC) method for the simultaneous determination of five phenolic acids in fried Fructus xanthii from various production sites and its dispensing granules, demonstrating good accuracy and repeatabil…

    DOI: 10.4103/0973-1296.111245
  32. <p>Pharmacist-led medication non-adherence intervention: reducing the economic burden placed on the Australian health care system</p> Patient Preference and Adherence (2019) Thin

    A retrospective, real-world analysis shows that a pharmacist-led adherence intervention using dispensing data improved adherence for three medications and reduced national non-adherence costs in Australia by about 1.9 billion AUD annually.

    DOI: 10.2147/ppa.s191482
  33. Sacubitril/valsartan (Entresto) utilisation and prescribing patterns in the context of a reimbursement application system British Journal of Clinical Pharmacology (2020) Thin

    A national Irish study describing the uptake and real-world characteristics of sacubitril/valsartan (Entresto) under a reimbursement system, comparing patient profiles to the PARADIGM-HF trial and examining changes in cardiovascular medication use and adherence after initiation.

    DOI: 10.1111/bcp.14393
  34. Long-Term Stability of the Electronic Sensor Component of a Digital Pill System in Real-World Storage Settings Journal of Pharmacy Technology (2021) Thin

    This study demonstrates that the electronic sensor component of a digital pill (ID-Cap system) remains stable and functional after long-term real-world storage, with rapid activation and sustained RF emission that meet system guidelines.

    DOI: 10.1177/8755122520985219
  35. Patient and clinician perspectives of an integrated electronic medication prescribing and dispensing system: A qualitative study at a multisite Australian hospital network Health Information Management Journal (2017) Thin

    Integrated e-prescribing and dispensing is perceived to improve medication safety, access to information, and workflow for both patients and clinicians, with patients prioritizing information access and privacy and clinicians prioritizing workflow-related features.

    DOI: 10.1177/1833358317720601
  36. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death International Journal of STD & AIDS (2004) Thin

    In a population-based HIV cohort, pharmacy dispensing records were used to quantify HAART adherence and showed that higher adherence predicts longer time to virologic failure, greater CD4 immune recovery, and lower risk of progression to AIDS or death, with low adherence yieldin…

    DOI: 10.1258/0956462042563666

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →